Is a C-TELOPEPTIDE (C-terminal telopeptide) serum level of 293 pg/mL appropriate for tooth extraction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CTX Level of 293 pg/mL is Appropriate for Tooth Extraction

A serum CTX level of 293 pg/mL is well above the 150 pg/mL threshold and indicates low risk for bisphosphonate-related osteonecrosis of the jaw (BRONJ), making tooth extraction appropriate to proceed. 1, 2

Risk Stratification Based on CTX Values

The critical threshold for BRONJ risk assessment is CTX < 150 pg/mL, which defines the "risk zone" for developing osteonecrosis after dentoalveolar surgery 1, 2:

  • CTX ≥ 150 pg/mL: Low risk - proceed with extraction under standard protocols 1, 2
  • CTX < 150 pg/mL: Elevated risk - consider drug holiday if medically appropriate before extraction 1, 2

Your patient's CTX of 293 pg/mL places them in the low-risk category, nearly double the safety threshold 1.

Evidence Supporting the 150 pg/mL Threshold

A large prospective study of 950 patients undergoing 2,461 extractions demonstrated that CTX < 150 pg/mL had 100% sensitivity for predicting BRONJ development 1. All four patients who developed BRONJ in this cohort had CTX levels below 150 pg/mL, while patients with CTX > 150 pg/mL had only a 0.13% risk compared to 0.42% risk for those below the threshold 1.

Multiple studies confirm this threshold 3, 2, 4:

  • CTX < 150 pg/mL carries a 5.3-fold increased odds ratio for BRONJ development (P = 0.004) 4
  • The "risk zone" extends from 150-200 pg/mL, with values below 150 pg/mL representing highest concern 2

Clinical Context: Bisphosphonate Use

This CTX threshold applies primarily to patients on oral bisphosphonates for osteoporosis 1, 2. The risk profile differs significantly:

  • Oral bisphosphonates: BRONJ risk approximately 0.2-0.4% after extraction when CTX < 150 pg/mL 1
  • Intravenous bisphosphonates (for cancer): Much higher risk (51.8% in one study), and CTX testing may be less predictive 4

Important Caveats About CTX Testing

While your patient's CTX level is reassuring, recognize these limitations:

  • CTX does not predict individual patient risk definitively - it identifies population-level risk stratification 2
  • Radiographic findings may be more sensitive: periodontal ligament widening around the tooth to be extracted was present in 83% of BRONJ cases versus only 11% of normal healing cases 3
  • CTX values vary with multiple factors including time of day, fasting status, renal function, and specific bisphosphonate type (alendronate associated with lower CTX than risedronate) 2

Recommended Extraction Protocol

For your patient with CTX 293 pg/mL, proceed with extraction using these precautions 1, 2:

  • Perform extraction under local anesthesia with conservative surgical technique 1, 4
  • Prescribe perioperative antibiotics for 7 days 4
  • Consider perioperative chlorhexidine mouth rinses (before procedure and three times daily for 5 days postoperatively) 5
  • Ensure primary closure when possible and minimize bone trauma 1
  • Follow until complete healing is confirmed 1

When to Consider Drug Holiday

A drug holiday is not indicated for your patient given the CTX of 293 pg/mL 1, 2. Drug holidays should only be considered when:

  • CTX < 150 pg/mL AND
  • Medically appropriate to discontinue bisphosphonate (no contraindication from osteoporosis severity or fracture risk) 1, 2

If a drug holiday were needed, CTX increases approximately 25 pg/mL per month after bisphosphonate cessation 2.

References

Research

A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2014

Research

Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009

Research

Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010

Research

Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.